KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Gains from Investment Securities (2020 - 2025)

Historic Gains from Investment Securities for AbCellera Biologics (ABCL) over the last 6 years, with Q3 2025 value amounting to $2.5 million.

  • AbCellera Biologics' Gains from Investment Securities fell 9022.22% to $2.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$9.3 million, marking a year-over-year decrease of 12360.85%. This contributed to the annual value of $19.7 million for FY2024, which is 4395.91% up from last year.
  • AbCellera Biologics' Gains from Investment Securities amounted to $2.5 million in Q3 2025, which was down 9022.22% from $2.6 million recorded in Q2 2025.
  • In the past 5 years, AbCellera Biologics' Gains from Investment Securities registered a high of $25.1 million during Q3 2024, and its lowest value of -$16.2 million during Q4 2024.
  • Over the past 5 years, AbCellera Biologics' median Gains from Investment Securities value was $4.5 million (recorded in 2023), while the average stood at $5.1 million.
  • Per our database at Business Quant, AbCellera Biologics' Gains from Investment Securities soared by 4345357.14% in 2021 and then tumbled by 56544.88% in 2024.
  • AbCellera Biologics' Gains from Investment Securities (Quarter) stood at $3.2 million in 2021, then surged by 83.62% to $5.9 million in 2022, then tumbled by 41.17% to $3.5 million in 2023, then crashed by 565.45% to -$16.2 million in 2024, then surged by 115.15% to $2.5 million in 2025.
  • Its Gains from Investment Securities stands at $2.5 million for Q3 2025, versus $2.6 million for Q2 2025 and $1.9 million for Q1 2025.